Efficacy and safety of sofosbuvir and daclatasvir in treatment of kidney transplantation recipients with hepatitis C virus infection

AIM To assess the efficacy and safety of sofosbuvir and daclatasvir regimens for kidney transplantation(KT) patients with hepatitis C virus(HCV) infection.METHODS This study enrolled a prospective cohort of consecutive Chinese KT patients with HCV infection. They were given sofosbuvir combined with...

Full description

Saved in:
Bibliographic Details
Published in:World journal of gastroenterology : WJG 2017-08, Vol.23 (32), p.5969-5976
Main Authors: Xue, Yan, Zhang, Li-Xin, Wang, Lei, Li, Tao, Qu, Yun-Dong, Liu, Feng
Format: Article
Language:English
Subjects:
Adult
Antiviral Agents - therapeutic use
China
Drug Therapy, Combination - methods
Graft Rejection - prevention & control
Graft Rejection - virology
Hepacivirus - genetics
Hepatitis C, Chronic - complications
Hepatitis C, Chronic - drug therapy
Hepatitis C, Chronic - virology
Humans
Imidazoles - therapeutic use
Kidney Transplantation - adverse effects
Liver Cirrhosis - prevention & control
Liver Cirrhosis - virology
Male
Middle Aged
Pilot Projects
Prospective Studies
Prospective Study
Ribavirin - therapeutic use
RNA, Viral - isolation & purification
Sofosbuvir - therapeutic use
Transplant Recipients
Treatment Outcome
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:AIM To assess the efficacy and safety of sofosbuvir and daclatasvir regimens for kidney transplantation(KT) patients with hepatitis C virus(HCV) infection.METHODS This study enrolled a prospective cohort of consecutive Chinese KT patients with HCV infection. They were given sofosbuvir combined with daclatasvir, with or without ribavirin. They were monitored regularly during and after the treatment. RESULTS Six patients were recruited in our prospective study cohort. All patients were male and naive to directacting antiviral treatment. The treatment duration was 12 wk. Most patients(4/6) were infected with HCV genotype 1b. HCV RNA was undetectable at week 4 after treatment and at the end of treatment in all patients. Sustained virological response rate at 12 wk was 100%(6/6). Two patients had to accept a half dose of sofosbuvir due to serum creatinine elevation during treatment. Kidney function in the remaining patients was stable. No serious adverse events(AEs) were observed. No patient discontinued antiviral therapy due to side effects. CONCLUSION Sofosbuvir and daclatasvir for treatment of KT recipients with HCV infection are highly efficient and safe. Patients tolerated the medications well, and no serious AEs were observed. Larger prospective cohort studies are needed to validate these results.
ISSN:1007-9327
2219-2840
DOI:10.3748/wjg.v23.i32.5969